Emergent Biosolutions (EBS) Tops Q1 EPS by 13c; Guides Q2 Sales
Emergent Biosolutions (NYSE: EBS) reported Q1 EPS of ($0.02), $0.13 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $50.3 million versus the consensus estimate of $47.32 million.
Sees Q2 2012 revenue of $70-$80 million, versus the consensus of $76.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Sees Q2 2012 revenue of $70-$80 million, versus the consensus of $76.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.